The non-muscle invasive bladder cancer market is witnessing significant growth due to the rising global incidence of bladder cancer, advancements in immunotherapy, targeted treatments, and launch of novel therapies such as CG0070 (cretostimogene grenadenorepvec) (CG Oncology), EG-70 (detalimogene…

Read the full release →

News provided by PR Newswire.